Another piece in Pfizer's booming biosimilars empire

3 April 2020
pfizer-logo-big

Europe’s medicines regulator has approved a biosimilar of Rituxan/MabThera (rituximab), developed by Pfizer (NYSE: PFE).

Branded Ruxience, the monoclonal antibody is cleared for marketing in multiple indications including non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA).

Approved in the USA in July 2019, Ruxience is part of a growing American market for biosimilars of the blockbuster biologic, with Celltrion (Kosdaq: 068270) and Teva Pharmaceutical (NYSE: TEVA) debuting their version, Truxima, in late 2019.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars